- Home
- SION vs KURA Comparison
SION vs KURA Comparison
Compare SION & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SION
- KURA
- Stock Information
- Founded
- SION 2019
- KURA 2014
- Country
- SION United States
- KURA United States
- Employees
- SION N/A
- KURA N/A
- Industry
- SION
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SION
- KURA Health Care
- Exchange
- SION NYSE
- KURA Nasdaq
- Market Cap
- SION 564.4M
- KURA 561.9M
- IPO Year
- SION 2025
- KURA N/A
- Fundamental
- Price
- SION $17.70
- KURA $5.84
- Analyst Decision
- SION Strong Buy
- KURA Strong Buy
- Analyst Count
- SION 1
- KURA 12
- Target Price
- SION $32.00
- KURA $24.50
- AVG Volume (30 Days)
- SION 241.3K
- KURA 1.3M
- Earning Date
- SION 08-25-2025
- KURA 08-07-2025
- Dividend Yield
- SION N/A
- KURA N/A
- EPS Growth
- SION N/A
- KURA N/A
- EPS
- SION N/A
- KURA N/A
- Revenue
- SION N/A
- KURA $67,991,000.00
- Revenue This Year
- SION N/A
- KURA $109.86
- Revenue Next Year
- SION N/A
- KURA $107.90
- P/E Ratio
- SION N/A
- KURA N/A
- Revenue Growth
- SION N/A
- KURA N/A
- 52 Week Low
- SION $7.26
- KURA $5.41
- 52 Week High
- SION $25.19
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- SION N/A
- KURA 39.08
- Support Level
- SION N/A
- KURA $5.73
- Resistance Level
- SION N/A
- KURA $6.01
- Average True Range (ATR)
- SION 0.00
- KURA 0.30
- MACD
- SION 0.00
- KURA -0.09
- Stochastic Oscillator
- SION 0.00
- KURA 3.68
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.